There is actually 70 m savings in operating expenses , so Mayne is operating both Nexstellis and TXMD at profit for the first time , so they are correct 14 m +ve contribution and international segment always making profit , hopefully they add more dermatology products from similar companies to use the existing sales force . Smart idea
Ann: 2023 Full Year Results Investor Presentation, page-34
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.38 |
Change
0.020(0.46%) |
Mkt cap ! $372.6M | |||
| Open | High | Low | Value | Volume |
| $4.37 | $4.48 | $4.37 | $395.4K | 89.43K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2324 | $4.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.41 | 140 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| MYX (ASX) Chart |